Precision Prostate Cancer Management

Gene fusion rearrangements point to emerging biomarkers and therapeutic opportunities

By Nallasivam Palanisamy 08/08/2025 Future 3 min read

Prostate cancer shows significant heterogeneity requiring stratification.
Identification of gene fusions aids in classifying tumors.
Non-ETS fusions like SLC45A3-BRAF have oncogenic potential.
KLK4-KLKP1 fusion is detectable in urine, aiding non-invasive monitoring.
Comprehensive profiling is critical for personalized therapy.
Future research will focus on transcriptomic analyses of treatment-resistant tumors.
Personalized approaches could guide targeted therapies for prostate cancer patients.

About the Author(s)

Associate Scientist at the Department of Urology, Henry Ford Health, and Associate Professor of Research at Michigan State University